Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIG1 | P18858 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799838 | 0.89 | ALDH1A1 (0.51) | LIG1CAPN1KDM4EMEN1KMT2A | |
| SCHEMBL22799717 | 0.77 | CAPN1 (0.47) | CAPN1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL22799711 | 0.77 | CAPN1 (0.47) | CAPN1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL22800135 | 0.74 | CAPN1 (0.49) | CAPN1CTSS | |
| SCHEMBL22800306 | 0.73 | CTSS (0.39) | CAPN1CTSS | |
| SCHEMBL22251169 | 0.72 | HPGD (0.58) | KDM4EMEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL385973 | 0.72 | HSP90AA1 (0.59) | KDM4EMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL22800999 | 0.71 | CAPN1 (0.47) | CAPN1CTSS | |
| SCHEMBL3808054 | 0.70 | KMT2A (0.50) | KDM4EMEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL24863013 | 0.70 | CAPN1 (0.66) | CAPN1HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | LIG1 4527/4885CAPN1 3/4885KDM4E 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.